Compare market size and growth of key Healthcare markets

Compare market size and growth of key Healthcare markets

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Loading...

Categories

11 Brazil Hyperglycemics Reports

Latin America Biguanide Industry

Country Covered: Brazil

Study Period: 2019 - 2030

Major Players: Bristol-Myers Squibb, Boehringer Ingelheim, Merck, Sanofi, Glenmark Pharmaceuticals

Latin America Human Insulin Drugs Industry

Country Covered: Brazil

Study Period: 2019 - 2030

Major Players: Novo Nordisk, Eli Lilly and Company, Sanofi, Biocon, Pfizer

Latin America Meglitinide Industry

Country Covered: Brazil

Study Period: 2019 - 2030

Major Players: Novo Nordisk, Glenmark Pharmaceuticals, KISSEI PHARMACEUTICAL, Novartis, Biocon

Meglitinides Market

Country Covered: Brazil

Study Period: 2019 - 2030

Major Players: Glenmark Pharmaceuticals, Novartis, KISSEI PHARMACEUTICAL, Biocon, Novo Nordisk

Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market

Country Covered: Brazil

Study Period: 2019 - 2030

Fibrate Drugs Market

Country Covered: Brazil

Study Period: 2019 - 2030

Major Players: Abbott Laboratories, Sanofi, Mylan, Lupin, Aurobindo Pharma

Glargine Insulin Market

Country Covered: Brazil

Study Period: 2019 - 2030

Major Players: Sanofi, Novo Nordisk, Biocon, Eli Lilly and Company, Julphar

Basal Insulin (Long-Acting Insulin) Market

Country Covered: Brazil

Study Period: 2019 - 2030

Major Players: Novo Nordisk, Sanofi, Eli Lilly and Company, Biocon, Wockhardt

Insulin Market

Country Covered: Brazil

Study Period: 2019 - 2030

Major Players: Novo Nordisk, Eli Lilly and Company, Pfizer, Sanofi, Biocon

Sulfonylureas Industry

Country Covered: Brazil

Study Period: 2019 - 2030

Major Players: Sanofi, Pfizer, Merck, Torrent Pharmaceuticals, Dr. Reddy’s Laboratories

Biguanides Market

Country Covered: Brazil

Study Period: 2019 - 2030

Major Players: Bristol-Myers Squibb, Glenmark Pharmaceuticals, Takeda Pharmaceuticals, Sanofi, Merck